In the bitter winters of 1944–1945, the Scandinavian volunteers of the Waffan SS faced the relentless Soviet onslaught at ...

Viking Therapeutics presents a high-risk, high-reward opportunity in the exploding GLP-1 weight loss market, where early clinical data for its VK2735 drug shows competitive results against current ...

Forbes contributors publish independent expert analyses and insights. Former editor of Robb Report, Debbi has written about luxuries from Asprey to Zegna.

Dubbed “violent chancers” by historian Guy Halsall, they seized abandoned land and valuable resources such as tar, furs and iron for weapons. They developed multiple, competing chiefdoms which they ...

At $24 versus the $89 analyst average price target, Viking trades at a steep discount. While some targets will likely be revised lower, the size of the decline appears excessive for a company with no ...

Viking stories have charmed audiences for centuries, though they've mostly fallen out of favor in recent times. It's a pity, as the genre is a ton of fun when done right. The best Viking tales speak ...

McCarthy also threw two interceptions and missed a handful of open receivers in big moments, including the deep shot to Nailor on third-and-1 on the first possession after his fumble. But O’Connell ...

In Norse myth, the end doesn’t come quietly—it comes with gods falling, giants rising, and the world consumed in fire and ice ...

Three 1,200-year-old Viking ships that have stood the test of time are embarking on their final and possibly riskiest journey to their new forever home in Norway.

Viking Therapeutics (NASDAQ:VKTX) lost ~38% in the premarket on Tuesday after announcing that its oral tablet formulation of its GLP-1/GIP dual receptor agonist VK2735 caused up to 12.2% of weight ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

While the stock’s plunge erased billions in market value, some analysts are calling it a massive overreaction and a prime buying opportunity, while others argue the data reveal a drug that is ...